The DOI matches its Crossref record; 192 of the 192 references it cites were found in a registry or an index; 213 of the 289 sources its claims cite were checked for support.
ADHD in Adulthood: Clinical Presentation, Comorbidities, and Treatment Perspectives
Open accessAbstract
Attention-deficit/hyperactivity disorder (ADHD) in adults has become an increasingly recognized clinical entity, with growing attention in research and healthcare settings. ADHD can significantly affect multiple domains of adult functioning, including education, employment, interpersonal relationships, and both mental and physical health. However, despite the expanding body of literature, gaps in understanding persist. This narrative review synthesizes current evidence on adult ADHD. The literature was systematically searched in databases such as PubMed, Scopus, and PsycINFO using predefined keywords related to ADHD in adults. Inclusion criteria focused on peer-reviewed articles published between 2010 and 2025, addressing epidemiology, etiology, diagnosis, treatment, and functioning. Exclusion criteria included studies with pediatric populations only or lacking methodological rigor. ADHD in adults is prevalent worldwide, with considerable heterogeneity across studies. Its etiology involves complex interactions between genetic, neurobiological, and environmental factors. Clinical presentation in adulthood differs from childhood, with symptoms such as inattention, emotional dysregulation, and executive dysfunction predominating. Diagnostic challenges include retrospective assessment of childhood symptoms and comorbidity with mood and anxiety disorders. Pharmacotherapy and cognitive–behavioral interventions show efficacy, particularly when combined in integrated care models. ADHD negatively affects quality of life and occupational and social functioning and increases the risk of comorbid disorders, including psychoactive substance use. Adult ADHD is a multifaceted condition requiring a comprehensive, multidisciplinary approach to diagnosis and management. Future research should aim to refine diagnostic tools, explore neurobiological markers, and tailor interventions to individual profiles. Expanding knowledge on adult ADHD will improve identification, treatment outcomes, and overall quality of life for affected individuals.
Overview
CoChat Summary
## TL;DR
This is a narrative review of adult ADHD that synthesizes literature from 2010–2025 on epidemiology, etiology, neurobiology, diagnosis, treatment, and functioning. It concludes that adult ADHD is common, heterogeneous, frequently comorbid, and best managed with integrated pharmacological and psychosocial care.
## Key findings
- Adult ADHD prevalence is reported as about 3%–6% in adults, with a global estimate of approximately 2.8%; the review also notes a broader range of approximately 2.5%–6.7%.
- Around 60%–65% of people diagnosed in childhood continue to have symptoms as adults, and many adults are first diagnosed late: in the USA, 55.9% were first diagnosed at age 18 or older, and one clinical/primary care study found only 25% had a childhood diagnosis.
- Psychiatric comorbidity is very common: 50%–80% of adults with ADHD have at least one additional mental disorder; mood disorders affect about 50%, anxiety disorders 20%–50%, substance use disorders carry a twofold increased risk, and emotional dysregulation is estimated in roughly 34%–70% of adults.
- Treatment evidence supports stimulants as first-line and most efficacious medications, with non-stimulants also effective; CBT is described as the most validated psychological therapy, with moderate-to-large effects on symptom reduction and comorbid anxiety/depression.
- Functional impact is substantial: adults with ADHD show lower educational attainment, more employment instability, and in one cross-national survey had 8.4 excess sick days per year.
## Methods
- Narrative review, not a meta-analysis; the authors systematically searched PubMed, Scopus, Web of Science, and PsycINFO using ADHD-adult-related keywords and Boolean operators.
- Included peer-reviewed English or Polish articles from 2010–2025 focused on adults (≥18 years) and on epidemiology, etiology, neurobiology, diagnosis, treatment, functioning, or quality of life; excluded pediatric-only studies, non-scientific items, conference abstracts without full text, poor-quality studies, and pre-2010 papers without updated relevance.
- The analysis was qualitative synthesis with narrative review of themes, with quantitative numbers extracted where applicable.
## Limitations
- The paper states that it is not a formal meta-analysis, so it cannot provide pooled effect sizes or quantitative comparisons.
- The included literature is heterogeneous in diagnostic criteria, assessment tools, and sample characteristics, which limits comparability; this is stated in the paper.
- Much of the evidence relies on retrospective self-report of childhood symptoms, which the paper notes may introduce recall bias.
- Because the search ended in 2025 and the authors note the possibility of publication bias and exclusion of very recent publications, these are evident limitations from the text.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
128 Valid · 39 Not valid · 44 Not checked · 82 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The current evidence base supports conceptualizing ADHD–ASD overlap as a distinct hybrid phenotype rather than a mere comorbidity”
§ ADHD in Adulthood: Clinical Presentation, Comorbidities, and Treatment Perspectives > 2. Epidemiology of Adult ADHD > 2.1. Prevalence
What the sources say
- Disputedcites [48] Deserno, 2023, Probing the overarching continuum theory: Data-driven phenotypic clustering of children with ASD or ADHD, Eur. Child Adolesc. Psychiatry sourceExperimental — accuracy not yet measured
The Results (Community detection identifies subgroups that cross-diagnostic boundaries; page unavailable) report that children with both diagnoses appeared in multiple clusters, rather than a distinct hybrid group. The Conclusion (page unavailable) says the study cannot unambiguously characterize ADHD and ASD as separate entities or opposite ends of a spectrum. It therefore does not support presenting a distinct hybrid phenotype as the conclusion of the evidence. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
- Could not verifycites [49] Schweizer, T., Endres, D., Dziobek, I., and van Elst, L.T. (2024). Psychosocial therapeutic approaches for high-functioning autistic adults. Front. Psychiatry, 14. sourceExperimental — accuracy not yet measured
The Introduction and the Discussion’s ‘Overall assessment of the current evidence base’ address high-functioning autistic adults, co-occurring anxiety and depression, and psychosocial interventions. Searches for ADHD–ASD overlap and a distinct hybrid phenotype found no passage addressing that distinction in our copy. (LLM, conf=0.76)
- Disputedcites [50] Young, S., Hollingdale, J., Absoud, M., Bolton, P., Branney, P., Colley, W., Craze, E., Dave, M., Deeley, Q., and Farrag, E. (2020). Guidance for identification and treatment of individuals with attention deficit/hyperactivity disorder and autism spectrum disorder based upon expert consensus. BMC Med., 18. sourceExperimental — accuracy not yet measured
The Background (‘Co-occurring ADHD and ASD’; page not provided) describes the overlap as co-occurrence that confers ‘additive vulnerability and complexity,’ not as a distinct hybrid phenotype. The Results (‘Identification and assessment’; page not provided) likewise discusses establishing an additional comorbid diagnosis when both conditions are present. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“This, in turn, results in attenuated phasic (task-related) DA firing in response to salient stimuli, leading to a weakened “signal-to-noise” ratio in the PFC”
§ ADHD in Adulthood: Clinical Presentation, Comorbidities, and Treatment Perspectives > 3. Etiology and Neurobiology of Adult ADHD > 3.2. Neurotransmitter System Dysfunctions The “catecholamine hypothesis” remains the most robust neurochemical model of ADHD, positing a primary dysregulation in dopaminergic (DA) and noradrenergic (NE) signaling. The DA system is central to executive function, motivation, and reward processing. The predominant theory suggests a state of hypodopaminergic functioning, particularly within fronto-striatal pathways. This is supported by molecular imaging (PET/SPECT), which, despite some inconsistencies, meta-analytically points to increased DA transporter (DAT) density in the striatum [66]. Higher DAT availability would lead to excessive reuptake and thus lower synaptic DA levels. A more nuanced interpretation is the “dopamine signaling” hypothesis (also known as the tonic-phasic model). This model proposes that low tonic (baseline) DA levels, particularly in the prefrontal cortex (PFC), impair the optimal “tuning” of cortical networks. This, in turn, results in attenuated phasic (task-related) DA firing in response to salient stimuli, leading to a weakened “signal-to-noise” ratio in the PFC [67]. This weakened signal impairs the maintenance of working memory and attentional focus. Concurrently, dysregulation in the mesolimbic pathway is linked to altered reward processing and the “delay aversion” characteristic of ADHD [68]. The NE system, originating from the locus coeruleus, is critical for modulating arousal, vigilance, and the “top-down” control of executive functions within the PFC. NE modulates the firing of PFC pyramidal neurons via postsynaptic α2A-adrenoceptors, enhancing relevant network signals (the “signal”) and suppressing irrelevant ones (the “noise”) [69]. Noradrenergic dysregulation is thought to contribute directly to inattention and emotional lability. The clinical efficacy of NE reuptake inhibitors (e.g., atomoxetine) and α2A-agonists (e.g., guanfacine) in treating ADHD underscores the therapeutic importance of this system [69]. Latest evidence suggests a “multi-modular” chemical imbalance. Magnetic Resonance Spectroscopy (MRS) studies have identified alterations in the glutamate-glutamine cycle—the brain’s primary excitatory system—in the PFC and striatum. Given that glutamate signaling is tightly coupled with and modulates DA release, this suggests that fronto-striatal dysfunction in ADHD may be a product of imbalanced glutamate/GABA-DA interactions [70]. The serotonergic (5-HT) system has also been implicated, particularly in relation to impulsivity and the high rates of comorbid mood and anxiety disorders [71].
What the sources say
- Disputedcites [67] Véronneau-Veilleux, F., Robaey, P., Ursino, M., and Nekka, F. (2022). A mechanistic model of ADHD as resulting from dopamine phasic/tonic imbalance during reinforcement learning. Front. Comput. Neurosci., 16. sourceExperimental — accuracy not yet measured
The Results (§3.1) state the opposite relationship: in the model, lower tonic dopamine reduces autoreceptor occupancy and produces higher phasic dopamine peaks. The Discussion (§4) reports an approximately 40% increase in the phasic response. The paper does not establish the claimed weakened signal-to-noise ratio in the PFC. (LLM, conf=0.92)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Variants within the dopamine transporter gene (DAT1/SLC6A3) and the dopamine D4 receptor gene (DRD4, especially the 7-repeat allele) were repeatedly associated with increased ADHD risk”
§ ADHD in Adulthood: Clinical Presentation, Comorbidities, and Treatment Perspectives > 2. Epidemiology of Adult ADHD > 2.2. Risk Factors and Predictors The etiology of ADHD is most accurately conceptualized not as the consequence of a single etiological source but as a multifactorial neurodevelopmental condition arising from the interaction between genetic predisposition and environmental influences (G×E). These factors jointly shape brain development and influence the clinical emergence of ADHD across the lifespan [57,58]. Evidence from twin studies consistently demonstrates a robust genetic contribution to ADHD, with heritability estimates of approximately 74% [57,58]. This places ADHD among the most heritable psychiatric disorders, underscoring inherited neurobiological vulnerability as a central etiological component [50]. Importantly, the genetic influence on ADHD is substantial yet probabilistic—genetic liability increases susceptibility but does not determine the disorder in isolation. Initial molecular studies focused on candidate genes, particularly within dopaminergic and noradrenergic pathways, aligning with known mechanisms of stimulant medications [59]. Variants within the dopamine transporter gene (DAT1/SLC6A3) and the dopamine D4 receptor gene (DRD4, especially the 7-repeat allele) were repeatedly associated with increased ADHD risk [59,60]. These findings formed the basis of the classical dopaminergic hypothesis, emphasizing dysregulation of reward and executive function circuits. Nevertheless, individual genetic variants accounted for only small increments of risk. Subsequent genome-wide association studies (GWAS)—notably those conducted by large consortia such as the Psychiatric Genomics Consortium (PGC)—fundamentally reshaped understanding of ADHD genetics. These studies demonstrate that ADHD is not attributable to a single “ADHD gene,” but rather exhibits a highly polygenic architecture, in which hundreds to thousands of common genetic variants collectively contribute modest but additive effects [59]. Identified loci are enriched in genes expressed in the developing brain and involved in neurodevelopmental processes, reinforcing the biological foundations of the disorder [59]. In sum, genetic vulnerability constitutes the primary predictor of ADHD risk. However, it operates as a cumulative and probabilistic neurodevelopmental liability, which may remain latent or compensated until challenged by environmental or developmental stressors. This perspective explains both individual variability in symptom expression and the heterogeneity observed in clinical presentation. While genetics provides a foundation of vulnerability, environmental factors modulate the expression and timing of ADHD onset, particularly among individuals carrying elevated genetic risk. These influences occur across developmental windows. Prenatal and perinatal factors represent key environmental contributors. Maternal smoking [61] and alcohol exposure [62] during pregnancy are associated with increased ADHD risk, likely through neurotoxic effects on fetal development. Prematurity, low birth weight, and perinatal hypoxia have also been linked to subsequent ADHD, suggesting vulnerability due to subtle neural injury during critical periods of maturation [58]. Postnatal exposures include toxic and nutritional factors. Exposure to lead in childhood is associated with increased ADHD symptoms and executive dysfunction [63]. Nutritional insufficiencies, including low levels of omega-3 fatty acids and iron, have been implicated in symptom severity, though findings are less consistent [62]. The psychosocial environment plays a modulating role as well. Early adverse childhood experiences (ACEs), family conflict, low socioeconomic status, and neglect predict more severe ADHD trajectories and greater comorbidity (e.g., anxiety, oppositional symptoms) [64,65]. These exposures are best conceptualized not as primary causes of ADHD but as amplifiers of symptom burden among genetically susceptible individuals. A summary of key environmental risk domains and their putative neurodevelopmental mechanisms is presented in Figure 1. The convergence of genetic and environmental evidence supports a diathesis-stress model, indicating that neither genetic risk nor environmental exposure alone is sufficient to account for ADHD. Instead, gene-environment interactions (G×E) determine the likelihood, severity, and developmental timing of symptom expression [57]. Environmental influences exert differential effects depending on genotype, such that individuals with specific genetic profiles (e.g., variants in dopaminergic or serotonergic genes such as 5-HTTLPR) are more susceptible to the neurobehavioral impact of early adversity and psychosocial stress [57].
What the sources say
- Disputedcites [59] Demontis, 2019, Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder, Nat. Genet. sourceExperimental — accuracy not yet measured
The Results (Analysis of gene sets; page unavailable) report little evidence for effects in previously proposed ADHD candidate genes, with only SLC9A9 showing a weak association among the nine genes examined. The Discussion likewise says substantial effects were not observed in most previously reported candidate genes. The copy does not name DAT1/SLC6A3, DRD4, or the 7-repeat allele in these findings, so the contradiction is to the claim's broad assertion of repeated risk associations rather than a gene-specific result. (LLM, conf=0.73)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [60] Werling, 2019, Association study and a systematic meta-analysis of the VNTR polymorphism in the 3′-UTR of dopamine transporter gene and attention-deficit hyperactivity disorder, J. Neural Transm. sourceExperimental — accuracy not yet measured
The Introduction and Results report associations between DAT1/SLC6A3 variants and ADHD, particularly the 10-repeat allele in children and adolescents, while noting small effects and heterogeneity. The paper does not report a repeated association between the DRD4 7-repeat allele and increased ADHD risk; DRD4 appears in reference titles, not in the paper’s findings. (LLM, conf=0.88)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“with PET studies showing increased microglial activation in adults with ADHD [85]”
§ ADHD in Adulthood: Clinical Presentation, Comorbidities, and Treatment Perspectives > 3. Etiology and Neurobiology of Adult ADHD > 3.5. Additional Neuroimaging Findings in ADHD Beyond structural and functional abnormalities identified in cortical and subcortical regions, recent large-scale and multimodal studies have provided additional insights into the neurobiology of ADHD. The ENIGMA-ADHD consortium, using voxel-based morphometry and analyses of cortical thickness, surface area, and volume, revealed reduced surface area in frontal regions, the cingulate gyrus, and temporal areas in children, whereas findings in adults have been more inconsistent, with some studies showing similar reductions and others reporting no significant group differences. Such variability likely reflects the influence of age-related neurodevelopmental trajectories, medication exposure, and the heterogeneity of ADHD across the lifespan [72]. Complementing these structural findings, diffusion tensor imaging (DTI) has highlighted alterations in white matter integrity, with reductions in fractional anisotropy observed across projection, commissural, and association pathways. These disruptions in structural connectivity correlate with symptom severity and cognitive deficits, suggesting that impaired communication between brain regions contributes to attentional and executive dysfunctions [83]. Moreover, electrophysiological studies employing electroencephalography (EEG) consistently report reduced P3 amplitudes during sustained attention tasks in adults with ADHD. The P3 component, an event-related potential reflecting attentional allocation and working memory processes, is diminished in ADHD, indicating difficulties in monitoring and sustaining attention [84]. Taken together, evidence from structural MRI, DTI, and EEG underscores that ADHD is characterized not only by cortical and subcortical abnormalities but also by widespread disruptions in structural connectivity and neurophysiological processing, reinforcing the view of ADHD as a disorder of distributed brain network dysfunction. In summary, the neurobiology of adult ADHD is best described as a disorder of distributed network integrity. It begins with a high polygenic diathesis, which, when coupled with environmental insults, perturbs the development of critical neurochemical systems, particularly the catecholaminergic modulation of fronto-striatal-cerebellar circuits. This leads to subtle but significant alterations in brain structure (e.g., smaller subcortical volumes, compromised white matter tracts). Ultimately, these structural and chemical abnormalities cascade into the functional domain, manifesting as a dynamic disconnection syndrome. The inefficient “switching” and coordination between the DMN, CEN, and SN result in an unstable cognitive state, impaired executive control, and the core clinical symptoms of the disorder. Emerging research is now probing novel etiological pathways. This includes the role of neuroinflammation, with PET studies showing increased microglial activation in adults with ADHD [85], and the microbiome-gut-brain axis, which may influence both neuroinflammation and neurotransmitter synthesis [86]. The notable neurobiological heterogeneity across individuals also suggests that adult ADHD is likely not a monolithic entity but a heterogeneous clinical syndrome with multiple, potentially overlapping, neurobiological subtypes.
What the sources say
- Disputedcites [85] Dunn, 2019, Neuroinflammation as a risk factor for attention deficit hyperactivity disorder, Pharmacol. Biochem. Behav. sourceExperimental — accuracy not yet measured
The Conclusion (page unavailable) describes PET imaging of activated microglia as a tool that will allow future studies to assess neuroinflammation in patients with ADHD. It does not report PET findings in adults with ADHD; the PET evidence it mentions concerns unspecified subjects and is described as preliminary. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In clinical and community samples of adults with ADHD, the combined presentation is by far the most common, accounting for roughly 63.5% of cases [89].”
§ ADHD in Adulthood: Clinical Presentation, Comorbidities, and Treatment Perspectives > 4. Neuropsychological Features of Adult ADHD: Comorbidity and Diagnostic Challenges > 4.1. Neuropsychological Perspective on Symptoms of Adult ADHD
What the sources say
- Disputedcites [89] Bedawi, R.M., Al-Farsi, Y., Mirza, H., Al-Huseini, S., Al-Mahrouqi, T., Al-Kiyumi, O., Al-Azri, M., and Al-Adawi, S. (2024). Prevalence and Clinical Profile of Adults with ADHD Attending a Tertiary Care Hospital for Five Years. Int. J. Environ. Res. Public Health, 21. sourceExperimental — accuracy not yet measured
The Results (§3.6; page not supplied) say that 63.5% of cases had the inattentive subtype, not the combined presentation. The Discussion (§4) likewise says inattention predominated in this Omani hospital cohort; the study does not establish that the combined presentation predominates across clinical and community samples. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
157 more claims · 84 with their cited sources checked
Create a free account to see all 293 claims and to verify the 7 references still open.
- Probably not a substantial claim. 25
- It may state two separate claims as one. 119
Citations
Cites
Kessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., Faraone, S. V., Greenhill, L. L., Howes, M. J., Secnik, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.716 · Cited by 3,886
ADHD Working Group of the Psychiatric Genomics Consortium (PGC), Demontis, D., Early Lifecourse & Genetic Epidemiology (EAGLE) Consortium, 23andMe Research Team, Walters, R. K., Martin, J., Mattheisen, M., Als, T. D., Agerbo, E., Baldursson, G., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0269-7 · Cited by 2,203 · cited 4×
“Variants within the dopamine transporter gene (DAT1/SLC6A3) and the dopamine D4 receptor gene (DRD4, especially the 7-repeat allele) were repeatedly associated with increased ADHD risk [59,60].”
InfluentialLai, M.-C., Kassee, C., Besney, R., Bonato, S., Hull, L., Mandy, W., Szatmari, P., & Ameis, S. H. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30289-5 · Cited by 1,892 · cited 1×
“Across studies, 15–50% of adults with ADHD exhibit autistic traits or meet ASD diagnostic thresholds, while 15–35% of adults with ASD also fulfill ADHD [42,43].”
Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation
Shaw, P., Eckstrand, K., Sharp, W., Blumenthal, J., Lerch, J. P., Greenstein, D., Clasen, L., Evans, A., Giedd, J., & Rapoport, J. L. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707741104 · Cited by 1,819 · cited 1×
“While this delay (e.g., in reaching peak cortical thickness) is prominent in children [73], findings in adults are more heterogeneous.”
Cortese, S., Adamo, N., Del Giovane, C., Mohr-Jensen, C., Hayes, A. J., Carucci, S., Atkinson, L. Z., Tessari, L., Banaschewski, T., Coghill, D., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30269-4 · Cited by 1,716 · cited 1×
“Robust evidence supports the efficacy of stimulant medications (e.g., methylphenidate, amphetamines) and non-stimulants (e.g., atomoxetine) in reducing core symptoms of ADHD [142,143].”
Faraone, S. V., Banaschewski, T., Coghill, D., Zheng, Y., Biederman, J., Bellgrove, M. A., Newcorn, J. H., Gignac, M., Al Saud, N. M., Manor, I., et al. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.01.022 · Cited by 1,545 · cited 5×
“Prematurity, low birth weight, and perinatal hypoxia have also been linked to subsequent ADHD, suggesting vulnerability due to subtle neural injury during critical periods of maturation [58].”
InfluentialGenetics of attention deficit hyperactivity disorder
Faraone, S. V., & Larsson, H. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0070-0 · Cited by 1,338 · cited 5×
“Instead, gene-environment interactions (G × E) determine the likelihood, severity, and developmental timing of symptom expression [57].”
InfluentialEmotion Dysregulation in Attention Deficit Hyperactivity Disorder
Shaw, P., Stringaris, A., Nigg, J., & Leibenluft, E. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13070966 · Cited by 1,232 · cited 1×
“A recent systematic review estimates that emotional dysregulation is present in roughly 34–70% of adults with the disorder [103].”
Toward systems neuroscience of ADHD: a meta-analysis of 55 fMRI studies
Cortese, S., Kelly, C., Chabernaud, C., Proal, E., Di Martino, A., Milham, M. P., & Castellanos, F. X. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.11101521 · Cited by 1,067 · cited 1×
“At the same time, both functional and structural neuroimaging studies provide important insights into dysfunctions in brain networks involved in attention, impulsivity, and cognitive control—particularly within the prefrontal cortex, striatum, and limbic sys-tem [207].”
Song, P., Zha, M., Yang, Q., Zhang, Y., Li, X., & Rudan, I. (2021) · Journal of Global Health · doi:10.7189/jogh.11.04009 · Cited by 896 · cited 2×
“Estimates suggest that adult ADHD affects between 3% and 6% of the population, underscoring the need for better diagnostic awareness and tailored treatment approaches in clinical practice [2–5].”
Influential
Research works printed but not linked: 9
- Hrys, 2024, Aдaптaцiйний пoтeнцiaл ociб дopocлoгo вiкy з poзлaдoм дeфiцитy yвaги/гiпepaктивнocтi (PДУГ), Insight Psychol. Dimens. Soc., 12, 471
- Takizawa, 2013, Prefrontal activation during inhibitory control measured by near-infrared spectroscopy for differentiating between autism spectrum disorders and attention deficit hyperactivity disorder in adults, Neuroimage Clin., 4, 53
- Cubillo, 2006, Executive dysfunctions in adults with attention deficit hyperactivity disorder, Rev. Neurol., 43, 678
- 2012, Cognitive and executive functions in ADHD, Actas Esp. Psiquiatr., 40, 293
- (2025, August 06). Table 7, DSM-IV to DSM-5 Attention-Deficit/Hyperactivity Disorder Comparison, Available online: https://www.ncbi.nlm.nih.gov/books/NBK519712/table/ch3.t3/.
- (2025, August 10). Treatment in adult ADHD|Oxford Textbook of Attention Deficit Hyperactivity Disorder|Oxford Academic. Available online: https://academic.oup.com/book/24517/chapter-abstract/187669990?redirectedFrom=fulltext.
- Knecht, 2015, Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder, Neuropsychiatr. Dis. Treat, 11, 1359
- Biederman, 2006, The Effects of Attention-Deficit/Hyperactivity Disorder on Employment and Household Income, MedGenMed, 8, 12
- 2022, Marital Adjustment and Marital Conflict in Individuals Diagnosed with ADHD and Their Spouses, Noro Psikiyatr Ars, 59, 127
Cited by
Dietary Carbohydrates and ADHD Symptoms: A Systematic Review
Panayotova, G. G., & Hachmeriyan, A. (2026) · Nutrients · doi:10.3390/nu18101625 · Cited by 2
Petropoulos, A., Pergantis, P., Drosos, K., & Tafiadis, D. (2026) · Nutrients · doi:10.3390/nu18162664 · Cited by 2
“We emphasize that despite their clinical significance, communication difficulties in ADHD remain underrecognized and are frequently interpreted solely as secondary consequences of attentional dysfunction [16].”
Agboji, H., Obanye, J., & Agboji, A. (2026) · Psychiatry International · doi:10.3390/psychiatryint7020064 · Cited by 1
A review of attention-deficit/hyperactivity disorder: Causes, diagnosis, treatment, and impact
Bamgboye, O. C., Busari, S. M., Muojekwu, C. G., Obe, N. M., Owojuyigbe, V. O., Oyeleke, N. M., Chinyere, K. F., Adegbola, P. I., Lawrence, A., & Adekeye, A. O. (2026) · Acta Psychologica · doi:10.1016/j.actpsy.2026.107744
Neurodevelopmental reward dysregulation and addiction risk in ADHD
Custodio, R. J. P., Yi, E. C., Kim, B.-N., & Cheong, J. H. (2026) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-026-02370-3
Metadata
- Authors
- Bogdańska-Chomczyk, E., Majewski, M. K., & Kozłowska, A.
- Affiliations
- University of Warmia and Mazury in Olsztyn (PL)
- Corresponding author
- Kozłowska, Anna
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2025-11-14
- Volume
- 26
- Issue
- 22
- Pages
- 11020
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC12652008
- OpenAlex
- W4416199620
- Semantic Scholar
- aede940d934f405290b6edd2696c76e5237e1e79
- Cited by
- 15
- References
- 185
- Citations by year
- 2026: 15
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- The Minister of Science under “The Regional Initiative of Excellence Program” (RID/SP/0025/2024/01)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- adult ADHD, attention deficit hyperactivity disorder, comorbidities, mood disorders, anxiety disorders, substance use disorders, executive dysfunction, emotional dysregulation, pharmacotherapy, cognitive behavioral therapy, integrated care, quality of life, occupational functioning, social functioning, etiology, diagnosis
- MeSH terms
- Adult, Attention Deficit Disorder with Hyperactivity, Humans, Quality of Life, Comorbidity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ADHD in Adulthood: Clinical Presentation, Comorbidities, and Treatment Perspectives. https://app.cochat.ai/papers/10.3390/ijms262211020
- The paper
- Bogdańska-Chomczyk, E., Majewski, M. K., & Kozłowska, A. (2025). ADHD in Adulthood: Clinical Presentation, Comorbidities, and Treatment Perspectives. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262211020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
